Value
8.2/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 8.3 |
| Fwd P/E | 5.2 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 24.4x
- ▸PEG: 0.15
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
MannKind is growing revenue about 24% year over year but remains cash-burning with losses and misses, depends on a sole insulin supplier, and carries weak quality, so the large analyst-target upside is speculative.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
Quality of 3.8 reflects free cash flow at -1% of revenue, a Rule of 40 score of 23 (fail) and an operating margin of -900.1% flagged as margin compression. Quality breakdown | Free cash flow turns positive and quarterly EPS returns to at least breakeven. | →Stable |
| CounterA negative margin figure that large may reflect one-off items, but a persistent cash burn would pressure the balance sheet. | ||
Revenue grew 24% year over year, with quarterly revenue of $101.9M in September 2026 versus $82.1M a year earlier. Growth breakdown | Quarterly revenue reaches the $134M next-quarter estimate and keeps growing above 15% year over year. | →Stable |
| CounterRevenue fell sequentially from $109.4M to $101.9M, so the growth path is uneven. | ||
Amphastar is the sole insulin supplier for Afrezza, a HIGH concentration risk to product supply. Bear case | Supply continues without interruption and gross margin holds near current levels. | →Stable |
| CounterA supply disruption or price increase from a single supplier could halt sales with no alternate source. | ||
EPS missed in 3 of the last 4 quarters, with EPS of -$0.01 to -$0.05 versus estimates of $0.01 to $0.02, after earlier profitable quarters. Last 4 quarters | EPS returns to positive and meets or beats consensus in the next two quarters. | ↑Improving |
| CounterPercentage surprises are large because EPS values are near zero, so small dollar differences exaggerate the misses. | ||
Analyst target of $7.25 versus a $3.85 price implies 88.3% upside, with light analyst coverage and a 41% drawdown from the 52-week high. Analyst target | Price closes part of the gap to the target as revenue growth is converted into profit. | ↑Improving |
| CounterCoverage is light, targets for small biotechs are often cut, and a death cross shows the trend is still down. | ||
CounterA negative margin figure that large may reflect one-off items, but a persistent cash burn would pressure the balance sheet.
CounterRevenue fell sequentially from $109.4M to $101.9M, so the growth path is uneven.
CounterA supply disruption or price increase from a single supplier could halt sales with no alternate source.
CounterPercentage surprises are large because EPS values are near zero, so small dollar differences exaggerate the misses.
CounterCoverage is light, targets for small biotechs are often cut, and a death cross shows the trend is still down.
| Component | Sub-score |
|---|---|
| P/S | 8.3 |
| Fwd P/E | 5.2 |
| PEG | 10.0 |
| Analyst target | 9.0 |
| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.6 |
| FCF quality | 0.0 |
| Moat | 7.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
| Component | Sub-score |
|---|---|
| Rev growth | 8.5 |
| EPS growth | 10.0 |
| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.8 |
| OBV | 1.0 |
| MA position | 8.0 |
| Volume | 4.8 |
| Component | Sub-score |
|---|---|
| LLM sentiment | 5.7 |
| Analyst rating | 8.0 |
| Price target | 10.0 |
| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
| Component | Sub-score |
|---|---|
| value rank | 8.0 |
| quality rank | 3.4 |
| growth rank | 5.7 |
| Component | Sub-score |
|---|---|
| bollinger | 4.9 |
| support resistance | 3.9 |
| 52w position | 1.8 |
| gap | 6.0 |
| Component | Sub-score |
|---|---|
| short interest | 5.9 |
| days to cover | 4.4 |
| volatility | 0.0 |
| put call | 9.9 |
| implied vol | 0.0 |
| beta | 6.6 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 6.0 |
Quality below minimum threshold.
L1:HARD_BLOCK:QUALITY_FLOORSetupRange Bound — RSI 57 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($1.2B) below institutional reach
SuitabilitySpeculative — Drawdown -41% (>40% off 52w high), Binary industry: Biotechnology
The SELL_IF_HOLDING verdict reflects the DEATH_CROSS gate's HARD_BLOCK outcome against Growth at 9.2 and asymmetric R:R of 5.89.
The strongest dimensions are Growth at 9.2, Value at 8.2, and Sentiment at 7.9; the weakest are Catalyst at 3.2, Quality at 3.8, and Technical at 4.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 5.89 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifQuarterly revenue growth falls below 10% year over year for 2 consecutive quarters.
Trip ifAny Amphastar supply interruption lasts more than 1 quarter.
Trip ifFree cash flow falls below -5% of revenue from the current -1%.
Trip ifQuarterly EPS stays below -$0.02 for 2 consecutive quarters.
Trip ifPrice falls below the $3.58 stop level, more than 7% under the current $3.85.